Securities and Exchange Commission,
Washington, D.C. 20549
Schedule 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 7)
TUTOGEN MEDICAL, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
901 107 10 2
(CUSIP Number)
Thomas W. Pauken, Liquidating Trustee
Capital Partners II, Ltd. Liquidating Trust
(successor to Renaissance Capital Partners II, Ltd.)
5646 Milton Street, Suite 900
Dallas, Texas 75206
(214) 378-9340
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
March 19, 2004
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),
check the following box. [ ]
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the Schedule, including all exhibits. See section 240.13d-7(b) for
other parties to whom copies are to be sent.
CUSIP No. 901 107 10 2
(1) Names of reporting persons
I.R.S. Identification Nos. of above persons (entities only)
Capital Partners II, Ltd. Liquidating Trust 75-6590369
(2) Check the appropriate box if a member of a group [ ]
(3) SEC use only
(4) Source of funds
OO
(5) Check if disclosure of legal proceedings is required pursuant to
Items 2(d) or 2(e) [ ]
(6) Citizenship or place of organization
Texas
Number of shares beneficially owned by each reporting person with:
(7) Sole voting power
2,975,139
(8) Shared voting power
0
(9) Sole dispositive power
2,975,139
(10) Shared dispositive power
0
(11) Aggregate amount beneficially owned by each reporting person
2,975,139
(12) Check if the aggregate amount in Row (11) excludes certain shares
[ ]
(13) Percent of class represented by amount in Row (11)
18.91%
(14) Type of reporting person
OO
Item 1. Security and Issuer
The Schedule 13D filed by Renaissance Capital Partners II, Ltd. on
February 10, 1999 with respect to securities of Tutogen Medical, Inc., as
previously amended, is hereby further amended as set forth in this Amendment
No. 7. Except as amended herein, the disclosure contained in the original
Schedule 13D, as amended, remains in effect. Capitalized terms used but not
defined herein shall have the meanings ascribed in the original Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration
These Amendment No. 7 does not report the acquisition of any additional
securities.
Item 4. Purpose of Transaction
The Trust was organized for the purpose of conducting an orderly
liquidation of the assets of Renaissance Capital Partners II, Ltd. and had an
initial term of two years, ending on November 17, 2002.
As previously reported, the Trustee extended the term of the Trust an
additional year, until November 17, 2004, and he also permitted the
beneficiaries of the Trust to withdraw from the Trust, and have distributed to
them their pro rated shares of Tutogen common stock then held by the Trust.
As a result of the elections made by beneficiaries, on March 19, 2004, the
Trust began distributing 649,787 shares of Tutogen common stock, representing
the pro rata interests of beneficiaries who elected to withdraw from the
Trust. The Trust continues to own 2,975,139 shares of Tutogen common stock
after deducting all of the shares being distributed to withdrawing
beneficiaries.
Item 7. Material to be Filed as Exhibits.
None.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: March 19, 2004 CAPITAL PARTNERS II, LTD.
LIQUIDATING TRUST
By: /s/
Thomas W. Pauken
Liquidating Trustee